Chai Pengdi, Pu Xiuying, Ge Jun, Ren Sulin, Xia Xiaoyu, Luo Amiao, Wang Shiwei, Wang Xiaodong, Li Jianqiang
Jiangsu Theravac Bio-pharmaceutical CO., Ltd, No.699-18 Xuanwu Street, Nanjing, 210042, China.
School of Life Science and Engineering, Lanzhou University of Technology, Lanzhou, 730050, China.
Appl Microbiol Biotechnol. 2021 Feb;105(4):1683-1692. doi: 10.1007/s00253-021-11139-8. Epub 2021 Jan 29.
Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines were widely used since 1940s. The exceptional success of childhood vaccination is undisputed. However, the anti-diphtheria and tetanus antibody will decrease with the increase of age in human body. A boosting vaccine for tetanus and diphtheria in adult is recommended by WHO. Recombinant protein vaccine has the advantages of single component and high safety, which is one of the directions to develop boosting vaccines. Therefore, in this study, we evaluated a recombinant TTc and CRM197 combination vaccine (RTCV) that uses the fragment C (TTc) of tetanus toxin and the cross-reacting material 197 (CRM197) of the diphtheria toxin mutant. Our results displayed that RTCV (composed of 10 μg/mL TTc, 20 μg/mL CRM197 antigens, and 500 μg/mL aluminum adjuvants) could induce high levels of IgG and IgG1 antibody in mice, which were similar as those induced by DTaP. These results will provide technical support for a novel boosting vaccine against diphtheria and tetanus. KEY POINTS: • We successfully expressed CRM197 protein in E. coli BL21 (DE3) using pET26b (+) vector. • The anti-TTc and anti-CRM197 antibody titer (IgG) of RTCV was similar with DTaP.
白喉破伤风类毒素和无细胞百日咳（DTaP）疫苗自20世纪40年代以来被广泛使用。儿童疫苗接种取得的非凡成功是无可争议的。然而，人体中抗白喉和破伤风抗体水平会随着年龄增长而下降。世界卫生组织建议为成年人接种破伤风和白喉加强疫苗。重组蛋白疫苗具有单一组分和高安全性的优点，是开发加强疫苗的方向之一。因此，在本研究中，我们评估了一种重组破伤风毒素C片段（TTc）和白喉毒素突变体的交叉反应物质197（CRM197）联合疫苗（RTCV）。我们的结果显示，RTCV（由10μg/mL TTc、20μg/mL CRM197抗原和500μg/mL铝佐剂组成）可在小鼠体内诱导高水平的IgG和IgG1抗体，与DTaP诱导的抗体水平相似。这些结果将为一种新型的白喉和破伤风加强疫苗提供技术支持。要点：• 我们使用pET26b（+）载体在大肠杆菌BL21（DE3）中成功表达了CRM197蛋白。• RTCV的抗TTc和抗CRM197抗体效价（IgG）与DTaP相似。
